Vaxil Bio Ltd (TSE:VXL)
:VXL
Want to see TSE:VXL full AI Analyst Report?
Top Page
Vaxil Bio
(VXL)
Select Model
Select Model
Rating:51Neutral
Price Target:
C$0.27
▲(104.62% Upside)
Action:Reiterated
Date:05/10/26
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn). Technical indicators are supportive with strong upward momentum and a positive trend, but near-overbought readings reduce the margin of safety. Valuation is constrained by a negative P/E and no dividend data.
Positive Factors
Low leverage / Balance sheet strength
Low or effectively no debt and an increased equity base materially reduce financial risk and give management latitude to fund clinical programs. This structural balance-sheet strength extends runway and supports R&D spending and partnership negotiations over the next several months.
Negative Factors
No commercial revenue
The absence of product revenue and persistently negative operating results reflect a pre-commercial profile that cannot self-sustain operations. This structural lack of revenue forces reliance on external capital or partners, making program continuity sensitive to financing access and timing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / Balance sheet strength
Low or effectively no debt and an increased equity base materially reduce financial risk and give management latitude to fund clinical programs. This structural balance-sheet strength extends runway and supports R&D spending and partnership negotiations over the next several months.
Read all positive factors
Vaxil Bio (VXL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.06M
Dividend YieldN/A
Average Volume (3M)1.45K
Price to Earnings (P/E)0.8
Beta (1Y)-0.91
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.17
Shares Outstanding3,984,021
10 Day Avg. Volume1,125
30 Day Avg. Volume1,453
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio-2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vaxil Bio Business Overview & Revenue Model
Company Description
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial f...
How the Company Makes Money
As a clinical-stage biotechnology company, Vaxil Bio’s ability to generate recurring commercial revenue from product sales is not publicly verifiable here; null. In general, companies at this stage typically fund operations through a combination o...
Vaxil Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -2.00K | -25.00K |
| EBITDA | -179.00K | -178.00K | -252.00K | -582.00K | -961.00K |
| Net Income | 522.00K | -178.00K | -254.00 | -584.00K | -986.00K |
Balance Sheet | |||||
| Total Assets | 1.37M | 733.00K | 976.00K | 1.54M | 2.29M |
| Cash, Cash Equivalents and Short-Term Investments | 671.00K | 714.00K | 938.00K | 1.51M | 2.24M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.00K | 17.00K | 85.00K | 405.00K | 585.00K |
| Stockholders Equity | 1.36M | 716.00K | 891.00K | 1.14M | 1.70M |
Cash Flow | |||||
| Free Cash Flow | -170.00K | -240.00K | -561.00K | -734.00K | -1.08M |
| Operating Cash Flow | -170.00K | -240.00K | -561.00K | -734.00K | -1.08M |
| Investing Cash Flow | 266.00K | -250.00K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 127.00K | 0.00 | 0.00 | 0.00 | 1.81M |
Vaxil Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$1.06M | 0.79 | -10.30% | ― | ― | ― | |
47 Neutral | C$5.95M | -0.14 | 123.88% | ― | ― | 60.66% | |
46 Neutral | C$29.94M | -0.56 | -221.75% | ― | ― | 44.28% | |
42 Neutral | C$37.12M | -4.40 | -103.51% | ― | ― | 57.98% | |
| ― | C$2.04M | -1.60 | ― | ― | ― | 25.09% | |
43 Neutral | C$28.68M | -6.55 | ― | ― | ― | 10.32% |
* Healthcare Sector Average
TSE:VXL
Vaxil Bio
0.27
0.07
32.50%
TSE:APS
Aptose Biosciences
2.33
-0.04
-1.69%
TSE:MDNA
Medicenna Therapeutics Corp
0.54
-0.60
-52.63%
TSE:BCT
BriaCell Therapeutics
4.13
-45.37
-91.66%
TSE:BIOV
BioVaxys Technology
0.07
-0.33
-82.46%
TSE:DTC
Defence Therapeutics
0.50
-0.41
-45.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.